Treatment of Parkinson's disease with deprenyl (selegiline) and other monoamine oxidase inhibitors

摘要: Publisher Summary Monoamine oxidase (MAO) refers to a class of flavin-containing enzymes that promote the oxidative deamination monoamines. MAOs located in outer mitochondrial membrane neuronal and glial cells are categorized by A (MAO-A) B (MAO-B) forms based on distribution, substrate selectivity, inhibitor specificity. Deprenyl has been studied as an adjunctive therapy levodopa-treated Parkinson's disease (PD) patients, shown be beneficial patients experiencing motor fluctuations. MAO-B inhibitors such deprenyl, nialamide, tranylcypromine can prevent biotransformation 1-methyl-4-phenyl-l,2,3,6-tetrahy-dropyridine (MPTP) 1-methyl-4-phenylpyridinum (MPP + ) development Parkinsonism pretreated experimental animals exposed 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP). It is found α-tocopherol treatment did not influence need for levodopa or ameliorate features PD, there was no interaction between deprenyl α-tocopherol. significantly reduced risk disability requiring treatment.